Q-omics provides the consensus-scored ACER1 profile across patient tissues and cancer cell-line models. ACER1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ACER1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ACER1 RNA expression shows 12,305 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where ACER1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACER1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACER1 survival associations across molecular data types. ACER1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACER1 RNA expression–survival associations across cancer types. High ACER1 expression shows unfavorable associations in KIRC and KIRP, but favorable associations in CESC, LUAD, HNSC and LIHC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for ACER1 RNA expression.
This table summarizes ACER1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACER1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACER1 shows lower tumor expression in HNSC, UCEC, KIRP, KICH, LIHC and PRAD. The HNSC box plot shows higher ACER1 RNA expression in normal versus tumor tissue (log2 FC = −1.758, t-test p < 0.001).
This table shows molecular features associated with ACER1 in patient tissues and cancer cell lines. In patient samples, ACER1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACER1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUSC.
